Clinical Trials
172 trialsShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Alliance for Clinical Trials in Oncology
TAYLOR-003
Second Affiliated Hospital, School of Medicine, Zhejiang University
TAPUR
American Society of Clinical Oncology
FASCINATE-N
Fudan University
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
Sun Yat-sen University
Elacestrant in Advanced Triple Positive Breast Cancer
NYU Langone Health
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
H. Lee Moffitt Cancer Center and Research Institute
Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
Fox Chase Cancer Center
HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission
Memorial Sloan Kettering Cancer Center
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
University of Washington
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
A Study of Surgery and Radiotherapy in People With Breast Cancer
Memorial Sloan Kettering Cancer Center
SPECTACLE
Fudan University
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
Jonsson Comprehensive Cancer Center
I-SPY
QuantumLeap Healthcare Collaborative
NeoTHERa
University of Kansas Medical Center
UC HER
National Taiwan University Hospital
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
Massachusetts General Hospital
PHERGAIN-2
MedSIR
OPTIMAL-BC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Dana-Farber Cancer Institute
EUREKA
Rutgers, The State University of New Jersey
DTP
The Methodist Hospital Research Institute
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Peking University Cancer Hospital & Institute
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Hebei Medical University Fourth Hospital
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
TOP-REAL
SOLTI Breast Cancer Research Group
ctDNA in HER2+ EBC Neoadjuvant Treatment
Shanghai Jiao Tong University School of Medicine
BRIDGET
Duke University
IPATHER
SOLTI Breast Cancer Research Group
Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
Peking University Cancer Hospital & Institute
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
H. Lee Moffitt Cancer Center and Research Institute
Opti-HER2
National Medical Research Radiological Centre of the Ministry of Health of Russia
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery
University of Chicago
PETREMAC
Haukeland University Hospital
PATINA
Alliance Foundation Trials, LLC.
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
M.D. Anderson Cancer Center
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
M.D. Anderson Cancer Center
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Shanghai Jiao Tong University School of Medicine
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Dana-Farber Cancer Institute
TAYLOR
Second Affiliated Hospital, School of Medicine, Zhejiang University
RAGE
Georgetown University
DETERMINE
Cancer Research UK
BIS-Program
Gustave Roussy, Cancer Campus, Grand Paris
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
PANSY
Fudan University
DETERMINE
Cancer Research UK